OncLive TV

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the prognosis of patients with melanoma brain and/or central nervous system metastases.

Heinz-Josef Lenz, MD, FACP, discusses third-line treatment combination approaches in colorectal cancer.

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Daniel H. Ahn, DO, an oncologist, internist, and assistant professor of medicine at Mayo Clinic, discusses current limitations of targeted therapy in the colorectal cancer.

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Bradley J. Monk, MD, FACS, FACOG, discusses the limitations of current treatment options in metastatic or recurrent cervical cancer.

Sunandana Chandra, MD, MS, discusses unanswered questions regarding the utility of targeted therapy in melanoma.

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

Thomas Hope, MD, discusses challenges with 68Ga-PSMA-11 PET in men with intermediate- or high-risk prostate cancer.

Nilanjan Ghosh, MD, PhD, discusses the safety results from the phase 2 PILOT study with lisocabtagene maraleucel in non-Hodgkin lymphoma.

Manish A. Shah, MD, discusses the exciting updated results of the phase 2 DESTINY-Gastric01 study with fam-trastuzumab deruxtecan-nxki in HER2-expressing advanced gastric or gastroesophageal junction adenocarcinoma.

Heinz-Josef Lenz, MD, FACP, discusses factors to consider when choosing between regorafenib and trifluridine/tipiracil in the third-line treatment of patients with colorectal cancer.

Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.

Lori A. Leslie, MD, discusses current treatment options for patients with relapsed/refractory mantle cell lymphoma.

Richard L. Shapiro, MD, discusses the utility of complete lymph node dissection in melanoma.

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

Daniel H. Ahn, DO, discusses ​updated findings from the ​phase 3 KEYNOTE-177 trial in patients with newly diagnosed microsatellite instability–high/mismatch repair deficient metastatic colorectal cancer.

Matthew S. Davids, MD, MMSc, discusses the potential utility of moving the combination of ibrutinib and umbralisib into the frontline setting of chronic lymphocytic leukemia and mantle cell lymphoma.

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.

Rebecca C. Arend, MD, discusses the unmet needs in of patients with platinum-resistant ovarian cancer.

Rami Komrokji, MD, discusses the current treatment landscape in myelodysplastic syndrome.

Lori A. Leslie, MD, discusses the encouraging evolving treatment landscape in mantle cell lymphoma.

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

David O'Malley, MD, discusses the activity of ​the investigational antibody-drug conjugate mirvetuximab soravtansine in ovarian cancer.

Sunandana Chandra, MD, MS, discusses the incidence of targetable mutations in melanoma.

Lori A. Leslie, MD, discusses the role of BTK inhibitors in relapsed/refractory mantle cell lymphoma.

Caitlin Costello, MD, discusses sequencing challenges in multiple myeloma.

Gaël Roué, PhD, senior scientist at Josep Carreras Leukaemia Research Institute, discusses the next steps with the investigational BTK inhibitor TG-1701 in mantle cell lymphoma.